Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study

Ibrutinib as monotherapy versus combination therapy in Chinese patients with relapsed/refractory mantle cell lymphoma: A multicenter study

Abstract Background Ibrutinib has revolutionized the treatment of mantle cell lymphoma (MCL). Both ibrutinib monotherapy and ibrutinib‐based combination therapy are important salvage options for patients with relapsed/refractory (R/R) MCL. The real‐world efficacy and safety profile of the two strate...

Full description

Bibliographic Details
Main Authors: Yuchen Zhang, Panpan Liu, Jun Cai, Hongmei Jing, Liqun Zou, Huiqiang Huang, Yuanbin Wu, Wenyu Li, Liye Zhong, Xueli Jin, Xu Ye, Ru Feng, Huilai Zhang, Liling Zhang, Lie Lin, Xiuhua Sun, Yuyang Tian, Zhongjun Xia, Zhiming Li, He Huang, Yi Xia, Qingqing Cai
Format: Article
Language:English
Published: Wiley 2022-11-01
Series:Cancer Medicine
Subjects:
combination therapy
ibrutinib
mantle cell lymphoma
relapsed/refractory
Online Access:https://doi.org/10.1002/cam4.4765

Internet

https://doi.org/10.1002/cam4.4765

Similar Items